{"title":"The Role of Biomarkers in the Diagnosis and Management of Pneumonia","authors":"Sarah Sungurlu DO, Robert A. Balk MD","doi":"10.1016/j.idc.2023.12.005","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":13562,"journal":{"name":"Infectious disease clinics of North America","volume":"38 1","pages":"Pages 35-49"},"PeriodicalIF":6.1000,"publicationDate":"2024-01-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Infectious disease clinics of North America","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0891552023000910","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
生物标志物可用于社区获得性肺炎（CAP）患者的诊断、严重程度判断和预后。选定的生物标志物可提示细菌感染和抗生素治疗的必要性（C 反应蛋白、降钙素原、髓样细胞上表达的可溶性触发受体）。生物标志物可以区分需要住院治疗的 CAP 患者和需要入住重症监护室的严重 CAP 患者。以生物标志物为指导的抗生素治疗可在不影响疗效的前提下限制抗生素暴露，从而提高抗生素管理水平。作者讨论了生物标记物在诊断、确定严重程度、确定预后以及限制 CAP 和呼吸机相关肺炎患者抗生素暴露方面的作用。
期刊介绍：
Infectious Disease Clinics of North America updates you on the latest trends in the clinical diagnosis and management of patients with infectious diseases, keeps you up to date on the newest advances, and provides a sound basis for choosing treatment options. Each issue focuses on a single topic in infectious disease, including clinical microbiology, compromised host infections, gastrointestinal infections, global health, hepatitis, HIV/AIDS, hospital-acquired infections, travel medicine, infection control, bacterial infections, sexually transmitted diseases, urinary tract infections, and viral infections.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
